Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.10 is 23% above its 5-year average of -1.44, around the middle of its 5-year range (-2.18–-0.05).
26.71% above its 12-month average of -1.50.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.24.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 18 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.10
EARNINGS PER SHARE (EPS) AVG TTM
-1.50
EARNINGS PER SHARE (EPS) AVG 3Y
-1.66
EARNINGS PER SHARE (EPS) AVG 5Y
-1.44
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+26.71%
CURRENT VS 3Y AVG
+33.74%
CURRENT VS 5Y AVG
+23.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Prime Medicine, Inc.
Market Cap
$628.48M
Earnings Per Share (EPS)
-1.10
TTM Avg
-1.50
3Y Avg
-1.66
5Y Avg
-1.44
Market Cap
$634.67M
Earnings Per Share (EPS)
-1.15
TTM Avg
-1.06
3Y Avg
-1.18
5Y Avg
-1.14
Market Cap
$634.26M
Earnings Per Share (EPS)
-1.78
TTM Avg
-1.75
3Y Avg
-1.85
5Y Avg
-1.69
Market Cap
$638.60M
Earnings Per Share (EPS)
-0.36
TTM Avg
-0.59
3Y Avg
-0.49
5Y Avg
-0.39
Market Cap
$617.19M
Earnings Per Share (EPS)
-0.83
TTM Avg
-1.21
3Y Avg
-1.36
5Y Avg
-1.94
Market Cap
$600.01M
Earnings Per Share (EPS)
0.77
TTM Avg
0.08
3Y Avg
-1.29
5Y Avg
-0.21
Market Cap
$657.39M
Earnings Per Share (EPS)
-0.30
TTM Avg
-0.54
3Y Avg
-0.54
5Y Avg
-0.54
Market Cap
$592.60M
Earnings Per Share (EPS)
-0.88
TTM Avg
-0.85
3Y Avg
-1.91
5Y Avg
-1.52
Market Cap
$667.31M
Earnings Per Share (EPS)
-2.72
TTM Avg
-2.70
3Y Avg
-2.77
5Y Avg
-2.61
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) | $628.48M | -1.10 | -1.50 | -1.66 | -1.44 |
| SOPHiA GENETICS S.A. (SOPH)vs › | $634.67M | -1.15 | -1.06 | -1.18 | -1.14 |
| Aura Biosciences, Inc. (AURA)vs › | $634.26M | -1.78 | -1.75 | -1.85 | -1.69 |
| OmniAb, Inc. (OABI)vs › | $638.60M | -0.36 | -0.59 | -0.49 | -0.39 |
| Climb Bio, Inc. (CLYM)vs › | $617.19M | -0.83 | -1.21 | -1.36 | -1.94 |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.01M | 0.77 | 0.08 | -1.29 | -0.21 |
| Starling Oncology, Inc. (STLN)vs › | $657.39M | -0.30 | -0.54 | -0.54 | -0.54 |
| AngioDynamics, Inc. (ANGO)vs › | $592.60M | -0.88 | -0.85 | -1.91 | -1.52 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $667.31M | -2.72 | -2.70 | -2.77 | -2.61 |
| Annexon, Inc. (ANNX)vs › | $664.82M | -1.16 | -1.18 | -1.68 | -2.29 |
Trailing EPS (TTM)
$-1.10
Forward EPS (Est.)
$-0.97
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.35 |
| 2024-12-31 | -1.65 |
| 2023-12-31 | -2.18 |
| 2022-12-31 | -1.46 |
| 2021-12-31 | -1.92 |
| 2020-12-31 | -0.05 |
| 2019-12-31 | -0.03 |
